In HER2-positive BC, fibroblast growth factor receptor 4 (FGFR4) accelerates cystine uptake and Fe2+ effect via the β-catenin/TCF4-SLC7A11/FPN1 axis and inhibits ferroptosis [176], indicating that it can be a potential target in BC. Here, FGFR4 is linked to breast cancer.